1991–1992 | 2017 | ||||
---|---|---|---|---|---|

SCE | SCE |
P
| PWE |
P
| |

Age (years), median (IQR) | 16 (13–21) | 26 (20–34) | <0.001 | 24 (20–32) | <0.001 |

Age group | |||||

< 10 years, n (%)
| 8 (9.5) | 3 (2.7) | 1 (1.2) | ||

10–19 years, n (%)
| 49 (58.3) | 23 (20.5) | 18 (22.2) | ||

20–29 years, n (%)
| 21 (25.0) | 44 (39.3) | 34 (42.0) | ||

≥ 30 years, n (%)
| 6 (7.1) | 42 (37.5) | 28 (34.6) | ||

Crude age-specific prevalence^{a}
| <0.001 | <0.001 | |||

< 10 years, (%) | 2.5 | 0.4 | 0.1 | ||

10–19 years, (%) | 22.3 | 4.9 | 3.8 | ||

20–29 years, (%) | 16.3 | 11.6 | 9.0 | ||

≥ 30 years, (%) | 1.6 | 6.0 | 4.0 | ||

Age at onset (years), median (IQR) |
12 (8–15)^{b}
| na |
12 (10–14)^{c}
| 0.294 | |

Age group at onset | |||||

< 10 years, n (%)
| 21 (25.0) | 19 (24.4) | |||

10–19 years, n (%)
| 49 (58.3) | 57 (73.1) | |||

20–29 years, n (%)
| 5 (6.0) | 1 (1.3) | |||

≥ 30 years, n (%)
| 1 (1.2) | 1 (1.3) | |||

Years since onset of epilepsy, median (IQR) |
5 (2.0–7.5)^{b}
| na |
12.5 (7–21)^{b}
| <0.001 |